Cargando…

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer

BACKGROUND: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Keshan, Ruan, Hailong, Xu, Tianbo, Liu, Lei, Liu, Di, Yang, Hongmei, Zhang, Xiaoping, Chen, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983013/
https://www.ncbi.nlm.nih.gov/pubmed/29881290
http://dx.doi.org/10.2147/OTT.S159777
_version_ 1783328358265782272
author Wang, Keshan
Ruan, Hailong
Xu, Tianbo
Liu, Lei
Liu, Di
Yang, Hongmei
Zhang, Xiaoping
Chen, Ke
author_facet Wang, Keshan
Ruan, Hailong
Xu, Tianbo
Liu, Lei
Liu, Di
Yang, Hongmei
Zhang, Xiaoping
Chen, Ke
author_sort Wang, Keshan
collection PubMed
description BACKGROUND: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the researches in the mechanism of CRPC and therapy for CRPC, more and more landmark progress has been made in recent years. METHODS: A number of clinical and experimental studies were reviewed to indicate the novel advancement in the progressive mechanism and therapy of CRPC. RESULTS: The androgen receptor (AR) is still a vital driver in the progression of CRPC, while other multiple mechanisms also contribute to this progression, such as tumor immunity, cancer stem cells, epithelial–mesenchymal transition and DNA repair disorder. In terms of the therapeutic methods of CRPC, chemotherapy with drugs, such as docetaxel, has been the first-line therapy for CRPC for many years. Besides, newer agents, which target some of the above mechanisms, show additional overall survival benefits for CRPC patients. These therapies include drugs targeting the androgen axis pathway (androgen synthesis, androgen receptor splice variants, coactivators of AR and so on), PI3K-AKT pathway, WNT pathway, DNA repair, rearrangement of ETS gene, novel chemotherapy and immunotherapy, bone metastasis therapy and so on. Understanding these novel findings on the mechanisms of CRPC and the latest potential CRPC therapies will direct us for further exploration of CRPC. CONCLUSION: Through comprehensive consideration, the predominant mechanism of CRPC might be the AR signal axis concomitant with tumor microenvironment, stress, immunity, tumor microenvironment and so on. For CRPC therapy, targeting the AR axis pathway and chemotherapy are the first-line treatments at present. However, with the advancements in CRPC therapy made by the researchers, other novel potential methods will occupy more and more important position in the treatment of CRPC, especially the therapies targeting the tumor microenviroment, tumor immunity and DNA repair and so on.
format Online
Article
Text
id pubmed-5983013
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59830132018-06-07 Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer Wang, Keshan Ruan, Hailong Xu, Tianbo Liu, Lei Liu, Di Yang, Hongmei Zhang, Xiaoping Chen, Ke Onco Targets Ther Review BACKGROUND: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the researches in the mechanism of CRPC and therapy for CRPC, more and more landmark progress has been made in recent years. METHODS: A number of clinical and experimental studies were reviewed to indicate the novel advancement in the progressive mechanism and therapy of CRPC. RESULTS: The androgen receptor (AR) is still a vital driver in the progression of CRPC, while other multiple mechanisms also contribute to this progression, such as tumor immunity, cancer stem cells, epithelial–mesenchymal transition and DNA repair disorder. In terms of the therapeutic methods of CRPC, chemotherapy with drugs, such as docetaxel, has been the first-line therapy for CRPC for many years. Besides, newer agents, which target some of the above mechanisms, show additional overall survival benefits for CRPC patients. These therapies include drugs targeting the androgen axis pathway (androgen synthesis, androgen receptor splice variants, coactivators of AR and so on), PI3K-AKT pathway, WNT pathway, DNA repair, rearrangement of ETS gene, novel chemotherapy and immunotherapy, bone metastasis therapy and so on. Understanding these novel findings on the mechanisms of CRPC and the latest potential CRPC therapies will direct us for further exploration of CRPC. CONCLUSION: Through comprehensive consideration, the predominant mechanism of CRPC might be the AR signal axis concomitant with tumor microenvironment, stress, immunity, tumor microenvironment and so on. For CRPC therapy, targeting the AR axis pathway and chemotherapy are the first-line treatments at present. However, with the advancements in CRPC therapy made by the researchers, other novel potential methods will occupy more and more important position in the treatment of CRPC, especially the therapies targeting the tumor microenviroment, tumor immunity and DNA repair and so on. Dove Medical Press 2018-05-28 /pmc/articles/PMC5983013/ /pubmed/29881290 http://dx.doi.org/10.2147/OTT.S159777 Text en © 2018 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Wang, Keshan
Ruan, Hailong
Xu, Tianbo
Liu, Lei
Liu, Di
Yang, Hongmei
Zhang, Xiaoping
Chen, Ke
Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title_full Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title_fullStr Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title_full_unstemmed Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title_short Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
title_sort recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983013/
https://www.ncbi.nlm.nih.gov/pubmed/29881290
http://dx.doi.org/10.2147/OTT.S159777
work_keys_str_mv AT wangkeshan recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT ruanhailong recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT xutianbo recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT liulei recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT liudi recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT yanghongmei recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT zhangxiaoping recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer
AT chenke recentadvancesontheprogressivemechanismandtherapyincastrationresistantprostatecancer